Sun Pharmaceutical Industries Limited vs Zydus Lifesciences Limited
An objective side-by-side of SUNPHARMA and ZYDUSLIFE, both in Pharmaceuticals - Indian - Bulk Drugs & Formln: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-11-05 close
Latest results: SUNPHARMA Sep 2026 · ZYDUSLIFE Sep 2026
At a glance
- Sun Pharmaceutical Industries Limited is the larger company by market value, about 3.7 times the size of Zydus Lifesciences Limited.
- On trailing earnings, Zydus Lifesciences Limited trades at the lower P/E (28.1 against 40.0).
- Zydus Lifesciences Limited earns the higher return on equity (15.2% against 12.3%).
- Over three years Zydus Lifesciences Limited has grown profits faster (32% a year against 13%).
- Over the past year the share prices returned +7.4% (SUNPHARMA) and +21.0% (ZYDUSLIFE).
| Metric | Sun Pharmaceutical SUNPHARMA |
Zydus Lifesciences ZYDUSLIFE |
|---|---|---|
| Size and price | ||
| Market cap | ₹438,838 Cr | ₹119,002 Cr |
| Share price | ₹1,829.00 | ₹1,193.00 |
| Valuation | ||
| P/E | 39.99 | 28.14 |
| P/B | 4.92 | 4.28 |
| EV/EBITDA | 24.47 | 16.23 |
| PEG | 3.08 | 0.88 |
| Dividend yield | 0.9% | 0.1% |
| Profitability | ||
| ROE | 12.3% | 15.2% |
| ROCE | 21.0% | 21.0% |
| Operating margin | 29.3% | 27.0% |
| Sales (TTM) | ₹61,631 Cr | ₹30,378 Cr |
| Net profit (TTM) | ₹10,974 Cr | ₹4,229 Cr |
| Growth | ||
| Latest quarter sales YoY | +11.9% | +29.2% |
| Latest quarter profit YoY | -36.2% | -25.3% |
| Sales CAGR 3Y | +10.0% | +16.0% |
| Profit CAGR 3Y | +13.0% | +32.0% |
| Sales CAGR 5Y | +12.0% | +12.0% |
| Profit CAGR 5Y | +17.0% | +19.0% |
| Financial strength | ||
| Debt/Equity | 0.04 | 0.50 |
| Interest cover | 43.64 | 16.11 |
| Ownership | ||
| Promoter holding | 52.7% | 75.0% |
| Promoter change (4 qtrs) | -1.80 pp | +0.01 pp |
| Price performance | ||
| Return 1M | +1.38% | +2.89% |
| Return 3M | -5.72% | +6.41% |
| Return 1Y | +7.37% | +20.98% |
| Return YTD | +6.36% | +30.48% |
| Technical condition | ||
| Technical score | 63 | 83 |
| RS rating (1-99) | 66.00 | 82.00 |
| % vs 200-DMA | +1.05% | +14.80% |
| RSI (14) | 61.49 | 55.38 |
| % from 52-week high | -10.65% | -5.81% |
